Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: A randomised controlled trial investigating the effects on airway inflammation in asthma

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Pavord, Ian ^a   Woodcock, Ashley ^b   Parker, Debbie ^a   Rice, Leanne ^c  

^a GLENFIELD HOSPITAL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYSTEINE; CYSTEINYL-LEUKOTRIENE; DRUG DERIVATIVE; FLUTICASONE; FLUTICASONE PROPIONATE - SALMETEROL COMBINATION; FLUTICASONE PROPIONATE SALMETEROL COMBINATION; HISTAMINE; INTERLEUKIN 8; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; QUINOLINE DERIVATIVE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG; MALE; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SPUTUM; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ACETATES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; CYSTEINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; GREAT BRITAIN; HISTAMINE; HUMANS; INTERLEUKIN-8; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LUNG; MALE; QUINOLINES; SPIROMETRY; SPUTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 38149044298     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-67     Document Type: Article

References (14)

1. Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. Respir Med 2002, 96(Suppl A):S9-15. 10.1016/S0954-6111(02)90077-6, 11858564.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. NIH Publication number 02-3659. 2002, updated 2004. Date last accessed: February 10 2005., http://www.ginasthma.org
3. British Thoracic Society and Scottish Intercollegiate Guidelines network. British guidelines on the management of asthma. 2004, Date last accessed:February 10 2005., http://www.sign.ac.uk
4. Ram F, Cates C, Ducharme F. Long-acting β2 -agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2005, (1):CD003137.
5. Chapman ID, Foster A, Morley J. The relationship between inflammation and hyperreactivity of the airways in asthma. Clin Exp Allergy 1993, 23(3):168-171. 10.1111/j.1365-2222.1993.tb00877.x, 8472185.
6. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002, 57(10):875-879. 10.1136/thorax.57.10.875, 12324674.
7. Wardlaw AJ, Brightling CE, Green R, Woltmann G, Bradding P, Pavord ID. New insights into the relationship between airway inflammation and asthma. Clin Sci (Lond) 2002, 103(2):201-211.
8. Birring SS, Parker D, Brightling CE, Bradding P, Wardlaw AJ, Pavord ID. Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med 2004, 169:15-19. 10.1164/rccm.200308-1092OC, 14512269.
9. Nocker RE, Out TA, Weller FR, de Riemer MJ, Jansen HM, van der Zee JS. Induced sputum and bronchoalveolar lavage as tools for evaluating the effects of inhaled corticosteroids in patients with asthma. J Lab Clin Med 2000, 136(1):39-49. 10.1067/mlc.2000.107305, 10882226.
10. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, Holgate ST, Picado C, Menten J, Dass SB, Leff JA, Polos PG. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003, 327:891. 218809, 14563743, 10.1136/bmj.327.7420.891.
11. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001, 119(4):1021-1026. 10.1378/chest.119.4.1021, 11296164.
12. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003, 167:1232-1238. 10.1164/rccm.200209-1116OC, 12456382.
13. Ilowite J, Webb R, Friedman B, Kerwin E, Bird SR, Hustad CM, Edelman JM. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004, 92(6):641-648.
14. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998, 158:924-30.